Clinical trial
Neoadjuvant Treatment of Breast Cancer
NCT00254592 · University of California, Irvine, Other · Completed
Key facts
| NCT number | NCT00254592 |
|---|---|
| Title | Neoadjuvant Treatment of Breast Cancer |
| Official title | Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Nab-paclitaxel Plus or Minus Trastuzumab and Plus or Minus Bevacizumab in Treatment of Large or Inflammatory Breast Cancer-a Phase II Study |
| Lead sponsor | University of California, Irvine, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Doxorubicin, Cyclophosphamide, Carboplatin, Nab-paclitaxel, GM-CSF, Trastuzumab, Bevacizumab |
| Enrollment | 43 |
| Start date | Oct 1, 2005 |
| Primary completion | Sep 4, 2013 |
| Completion | Sep 4, 2013 |
| First posted | Nov 16, 2005 |
| Last update posted | Feb 28, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: